Obesity and its potential effects on antidepressant treatment outcomes in patients with depressive disorders: A literature review

International Journal of Molecular Sciences

Volumn 17, Issue 1, 2016, Pages

  Woo, Young Sup ^a,b   Seo, Hye Jin ^a   McIntyre, Roger S ^b,c   Bahk, Won Myong ^a  

^a The Catholic University of Korea   (South Korea)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antidepressant; Depressive disorder; Obesity; Response; Treatment outcome

Indexed keywords

ADIPOCYTOKINE; BIOLOGICAL MARKER; ESCITALOPRAM; GLYCOGEN SYNTHASE KINASE 3BETA; NORTRIPTYLINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; ANTIDEPRESSANT AGENT;

ANTIDEPRESSANT ACTIVITY; BODY WEIGHT; COGNITION; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; GENDER; GENOTYPE; HUMAN; INFLAMMATION; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NITROSATIVE STRESS; OBESITY; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; ADULT; AGE; BODY MASS; CLINICAL TRIAL (TOPIC); COMPLICATION; DEPRESSIVE DISORDER; FEMALE; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SEX DIFFERENCE;

ADULT; AGE FACTORS; ANTIDEPRESSIVE AGENTS; BODY MASS INDEX; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; PROGNOSIS; SEX FACTORS; TREATMENT OUTCOME;

EID: 84954306125     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17010080     Document Type: Review

References (171)

1. Nelson, J.C.; Papakostas, G.I. Atypical antipsychotic augmentation in major depressive disorder: A meta-analysis of placebo-controlled randomized trials. Am. J. Psychiatry 2009, 166, 980-991. [CrossRef] [PubMed]
2. Rush, A.J.; Trivedi, M.H.; Wisniewski, S.R.; Nierenberg, A.A.; Stewart, J.W.; Warden, D.; Niederehe, G.; Thase, M.E.; Lavori, P.W.; Lebowitz, B.D.; et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am. J. Psychiatry 2006, 163, 1905-1917. [CrossRef] [PubMed]
3. Vieta, E.; Colom, F. Therapeutic options in treatment-resistant depression. Ann. Med. 2011, 43, 512-530. [CrossRef] [PubMed]
4. Turner, P.; Kantaria, R.; Young, A.H. A systematic review and meta-analysis of the evidence base for add-on treatment for patients with major depressive disorder who have not responded to antidepressant treatment: A european perspective. J. Psychopharmacol. 2014, 28, 85-98. [CrossRef] [PubMed]
5. Nierenberg, A.A. Predictors of response to antidepressants general principles and clinical implications. Psychiatr. Clin. N. Am. 2003, 26, 345-352. [CrossRef]
6. Souery, D.; Oswald, P.; Massat, I.; Bailer, U.; Bollen, J.; Demyttenaere, K.; Kasper, S.; Lecrubier, Y.; Montgomery, S.; Serretti, A.; et al. Clinical factors associated with treatment resistance in major depressive disorder: Results from a european multicenter study. J. Clin. Psychiatry 2007, 68, 1062-1070. [CrossRef] [PubMed]
7. Dudek, D.; Rybakowski, J.K.; Siwek, M.; Pawlowski, T.; Lojko, D.; Roczen, R.; Kiejna, A. Risk factors of treatment resistance in major depression: Association with bipolarity. J. Affect. Disord. 2010, 126, 268-271. [CrossRef] [PubMed]
8. Bennabi, D.; Aouizerate, B.; El-Hage, W.; Doumy, O.; Moliere, F.; Courtet, P.; Nieto, I.; Bellivier, F.; Bubrovsky, M.; Vaiva, G.; et al. Risk factors for treatment resistance in unipolar depression: A systematic review. J. Affect. Disord. 2015, 171, 137-141. [CrossRef] [PubMed]
9. Toups, M.S.; Trivedi, M.H. Role of metabolic dysfunction in treatment resistance of major depressive disorder. Neuropsychiatry 2011, 1, 441-455. [CrossRef]
10. Papakostas, G.I.; Petersen, T.; Iosifescu, D.V.; Burns, A.M.; Nierenberg, A.A.; Alpert, J.E.; Rosenbaum, J.F.; Fava, M. Obesity among outpatients with major depressive disorder. Int. J. Neuropsychopharmacol. 2005, 8, 59-63. [CrossRef] [PubMed]
11. Khan, A.; Schwartz, K.A.; Kolts, R.L.; Brown,W.A. BMI, sex, and antidepressant response. J. Affect. Disord. 2007, 99, 101-106. [CrossRef] [PubMed]
12. Kloiber, S.; Ising, M.; Reppermund, S.; Horstmann, S.; Dose, T.; Majer, M.; Zihl, J.; Pfister, H.; Unschuld, P.G.; Holsboer, F.; et al. Overweight and obesity affect treatment response in major depression. Biol. Psychiatry 2007, 62, 321-326. [CrossRef] [PubMed]
13. Oskooilar, N.; Wilcox, C.S.; Tong, M.L.; Grosz, D.E. Body mass index and response to antidepressants in depressed research subjects. J. Clin. Psychiatry 2009, 70, 1609-1610. [CrossRef] [PubMed]
14. Dennehy, E.B.; Robinson, R.L.; Stephenson, J.J.; Faries, D.; Grabner, M.; Palli, S.R.; Stauffer, V.L.; Marangell, L.B. Impact of non-remission of depression on costs and resource utilization: From the comorbidities and symptoms of depression (CODE) study. Curr. Med. Res. Opin. 2015, 31, 1165-1177. [CrossRef] [PubMed]
15. Sagud, M.; Mihaljevic-Peles, A.; Uzun, S.; Cusa, B.V.; Kozumplik, O.; Kudlek-Mikulic, S.; Mustapic, M.; Barisic, I.; Muck-Seler, D.; Pivac, N. The lack of association between components of metabolic syndrome and treatment resistance in depression. Psychopharmacology 2013, 230, 15-21. [CrossRef] [PubMed]
16. Toups, M.S.; Myers, A.K.; Wisniewski, S.R.; Kurian, B.; Morris, D.W.; Rush, A.J.; Fava, M.; Trivedi, M.H. Relationship between obesity and depression: Characteristics and treatment outcomes with antidepressant medication. Psychosom. Med. 2013, 75, 863-872. [CrossRef] [PubMed]
17. Vogelzangs, N.; Beekman, A.T.; van Reedt Dortland, A.K.; Schoevers, R.A.; Giltay, E.J.; de Jonge, P.; Penninx, B.W. Inflammatory and metabolic dysregulation and the 2-year course of depressive disorders in antidepressant users. Neuropsychopharmacology 2014, 39, 1624-1634. [CrossRef] [PubMed]
18. Uher, R.; Mors, O.; Hauser, J.; Rietschel, M.; Maier, W.; Kozel, D.; Henigsberg, N.; Souery, D.; Placentino, A.; Perroud, N.; et al. Body weight as a predictor of antidepressant efficacy in the gendep project. J. Affect. Disord. 2009, 118, 147-154. [CrossRef] [PubMed]
19. Mansur, R.B.; Brietzke, E.; McIntyre, R.S. Is there a "metabolic-mood syndrome"? A review of the relationship between obesity and mood disorders. Neurosci. Biobehav. Rev. 2015, 52, 89-104. [CrossRef] [PubMed]
20. Kaestner, F.; Hettich, M.; Peters, M.; Sibrowski, W.; Hetzel, G.; Ponath, G.; Arolt, V.; Cassens, U.; Rothermundt, M. Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic major depression are associated with HPA axis activity. J. Affect. Disord. 2005, 87, 305-311. [CrossRef] [PubMed]
21. Lamers, F.; Vogelzangs, N.; Merikangas, K.R.; de Jonge, P.; Beekman, A.T.; Penninx, B.W. Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic vs. atypical depression. Mol. Psychiatry 2013, 18, 692-699. [CrossRef] [PubMed]
22. Angst, J.; Gamma, A.; Sellaro, R.; Zhang, H.; Merikangas, K. Toward validation of atypical depression in the community: Results of the zurich cohort study. J. Affect. Disord. 2002, 72, 125-138. [CrossRef]
23. Benazzi, F. Should mood reactivity be included in the DSM-IV atypical features specifier? Eur. Arch. Psychiatry Clin. Neurosci. 2002, 252, 135-140. [CrossRef] [PubMed]
24. Penninx, B.W.; Milaneschi, Y.; Lamers, F.; Vogelzangs, N. Understanding the somatic consequences of depression: Biological mechanisms and the role of depression symptom profile. BMC Med. 2013, 11. [CrossRef] [PubMed]
25. Lamers, F.; de Jonge, P.; Nolen, W.A.; Smit, J.H.; Zitman, F.G.; Beekman, A.T.; Penninx, B.W. Identifying depressive subtypes in a large cohort study: Results from the netherlands study of depression and anxiety (NESDA). J. Clin. Psychiatry 2010, 71, 1582-1589. [CrossRef] [PubMed]
26. Hasler, G.; Pine, D.S.; Gamma, A.; Milos, G.; Ajdacic, V.; Eich, D.; Rossler, W.; Angst, J. The associations between psychopathology and being overweight: A 20-year prospective study. Psychol. Med. 2004, 34, 1047-1057. [CrossRef] [PubMed]
27. Kendler, K.S.; Eaves, L.J.; Walters, E.E.; Neale, M.C.; Heath, A.C.; Kessler, R.C. The identification and validation of distinct depressive syndromes in a population-based sample of female twins. Arch. Gen. Psychiatry 1996, 53, 391-399. [CrossRef] [PubMed]
28. Raedler, T.J. Inflammatory mechanisms in major depressive disorder. Curr. Opin. Psychiatry 2011, 24, 519-525. [CrossRef] [PubMed]
29. Liu, C.S.; Carvalho, A.F.; McIntyre, R.S. Towards a "metabolic" subtype of major depressive disorder: Shared pathophysiological mechanisms may contribute to cognitive dysfunction. CNS Neurol. Disord. Drug Targets 2014, 13, 1693-1707. [CrossRef] [PubMed]
30. Blaine, B. Does depression cause obesity?: A meta-analysis of longitudinal studies of depression and weight control. J. Health Psychol. 2008, 13, 1190-1197. [CrossRef] [PubMed]
31. Lim,W.; Thomas, K.S.; Bardwell,W.A.; Dimsdale, J.E. Which measures of obesity are related to depressive symptoms and in whom? Psychosomatics 2008, 49, 23-28. [CrossRef] [PubMed]
32. Keers, R.; Aitchison, K.J. Gender differences in antidepressant drug response. Int. Rev. Psychiatry 2010, 22, 485-500. [CrossRef] [PubMed]
33. Tilg, H.; Moschen, A.R. Adipocytokines: Mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol. 2006, 6, 772-783. [CrossRef] [PubMed]
34. Berg, A.H.; Scherer, P.E. Adipose tissue, inflammation, and cardiovascular disease. Circ. Res. 2005, 96, 939-949. [CrossRef] [PubMed]
35. Gustafson, B.; Hammarstedt, A.; Andersson, C.X.; Smith, U. Inflamed adipose tissue: A culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 2276-2283. [CrossRef] [PubMed]
36. He, G.; Pedersen, S.B.; Bruun, J.M.; Lihn, A.S.; Jensen, P.F.; Richelsen, B. Differences in plasminogen activator inhibitor 1 in subcutaneous vs. omental adipose tissue in non-obese and obese subjects. Horm. Metab. Res. 2003, 35, 178-182. [CrossRef] [PubMed]
37. Winkler, G.; Kiss, S.; Keszthelyi, L.; Sapi, Z.; Ory, I.; Salamon, F.; Kovacs, M.; Vargha, P.; Szekeres, O.; Speer, G.; et al. Expression of tumor necrosis factor (TNF)-α protein in the subcutaneous and visceral adipose tissue in correlation with adipocyte cell volume, serum TNF-α, soluble serum TNF-receptor-2 concentrations and c-peptide level. Eur. J. Endocrinol. 2003, 149, 129-135. [CrossRef] [PubMed]
38. Maury, E.; Ehala-Aleksejev, K.; Guiot, Y.; Detry, R.; Vandenhooft, A.; Brichard, S.M. Adipokines oversecreted by omental adipose tissue in human obesity. Am. J. Physiol. Endocrinol. Metab. 2007, 293, E656-E665. [CrossRef] [PubMed]
39. Strawbridge, R.; Arnone, D.; Danese, A.; Papadopoulos, A.; Herane Vives, A.; Cleare, A.J. Inflammation and clinical response to treatment in depression: A meta-analysis. Eur. Neuropsychopharmacol. 2015, 25, 1532-1543. [CrossRef] [PubMed]
40. Carr, M.C. The emergence of the metabolic syndrome with menopause. J. Clin. Endocrinol. Metab. 2003, 88, 2404-2411. [CrossRef] [PubMed]
41. Zegura, B.; Guzic-Salobir, B.; Sebestjen, M.; Keber, I. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Menopause 2006, 13, 643-650. [PubMed]
42. Mueck, A.O.; Genazzani, A.R.; Samsioe, G.; Vukovic-Wysocki, I.; Seeger, H. Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: Transdermal vs. oral application. Menopause 2007, 14, 978-984. [CrossRef] [PubMed]
43. Vegeto, E.; Benedusi, V.; Maggi, A. Estrogen anti-inflammatory activity in brain: A therapeutic opportunity for menopause and neurodegenerative diseases. Front. Neuroendocrinol. 2008, 29, 507-519. [CrossRef] [PubMed]
44. Dheen, S.T.; Kaur, C.; Ling, E.A. Microglial activation and its implications in the brain diseases. Curr. Med. Chem. 2007, 14, 1189-1197. [CrossRef] [PubMed]
45. Kornstein, S.G.; Schatzberg, A.F.; Thase, M.E.; Yonkers, K.A.; McCullough, J.P.; Keitner, G.I.; Gelenberg, A.J.; Davis, S.M.; Harrison, W.M.; Keller, M.B. Gender differences in treatment response to sertraline vs. imipramine in chronic depression. Am. J. Psychiatry 2000, 157, 1445-1452. [CrossRef] [PubMed]
46. Martenyi, F.; Dossenbach, M.; Mraz, K.; Metcalfe, S. Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: A double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. Eur. Neuropsychopharmacol. 2001, 11, 227-232. [CrossRef]
47. Khan, A.; Brodhead, A.E.; Schwartz, K.A.; Kolts, R.L.; Brown,W.A. Sex differences in antidepressant response in recent antidepressant clinical trials. J. Clin. Psychopharmacol. 2005, 25, 318-324. [CrossRef] [PubMed]
48. Quitkin, F.M.; Stewart, J.W.; McGrath, P.J.; Taylor, B.P.; Tisminetzky, M.S.; Petkova, E.; Chen, Y.; Ma, G.; Klein, D.F. Are there differences between women's and men's antidepressant responses? Am. J. Psychiatry 2002, 159, 1848-1854. [CrossRef] [PubMed]
49. Young, E.A.; Kornstein, S.G.; Marcus, S.M.; Harvey, A.T.; Warden, D.; Wisniewski, S.R.; Balasubramani, G.K.; Fava, M.; Trivedi, M.H.; John Rush, A. Sex differences in response to citalopram: A STAR*D report. J. Psychiatr. Res. 2009, 43, 503-511. [CrossRef] [PubMed]
50. Parker, G.; Parker, K.; Austin, M.P.; Mitchell, P.; Brotchie, H. Gender differences in response to differing antidepressant drug classes: Two negative studies. Psychol. Med. 2003, 33, 1473-1477. [CrossRef] [PubMed]
51. Pinto-Meza, A.; Usall, J.; Serrano-Blanco, A.; Suarez, D.; Haro, J.M. Gender differences in response to antidepressant treatment prescribed in primary care. Does menopause make a difference? J. Affect. Disord. 2006, 93, 53-60. [CrossRef] [PubMed]
52. Kendall, D.A.; Stancel, G.M.; Enna, S.J. The influence of sex hormones on antidepressant-induced alterations in neurotransmitter receptor binding. J. Neurosci. 1982, 2, 354-360. [PubMed]
53. Halbreich, U.; Rojansky, N.; Palter, S.; Tworek, H.; Hissin, P.; Wang, K. Estrogen augments serotonergic activity in postmenopausal women. Biol. Psychiatry 1995, 37, 434-441. [CrossRef]
54. Gundlah, C.; Alves, S.E.; Clark, J.A.; Pai, L.Y.; Schaeffer, J.M.; Rohrer, S.P. Estrogen receptor-β regulates tryptophan hydroxylase-1 expression in the murine midbrain raphe. Biol. Psychiatry 2005, 57, 938-942. [CrossRef] [PubMed]
55. Hiroi, R.; McDevitt, R.A.; Neumaier, J.F. Estrogen selectively increases tryptophan hydroxylase-2 mRNA expression in distinct subregions of rat midbrain raphe nucleus: Association between gene expression and anxiety behavior in the open field. Biol. Psychiatry 2006, 60, 288-295. [CrossRef] [PubMed]
56. Lu, N.Z.; Bethea, C.L. Ovarian steroid regulation of 5-HT1A receptor binding and g protein activation in female monkeys. Neuropsychopharmacology 2002, 27, 12-24. [CrossRef]
57. Sell, S.L.; Craft, R.M.; Seitz, P.K.; Stutz, S.J.; Cunningham, K.A.; Thomas, M.L. Estradiol-sertraline synergy in ovariectomized rats. Psychoneuroendocrinology 2008, 33, 1051-1060. [CrossRef] [PubMed]
58. Westlund Tam, L.; Parry, B.L. Does estrogen enhance the antidepressant effects of fluoxetine? J. Affect. Disord. 2003, 77, 87-92. [CrossRef]
59. Schneider, L.S.; Small, G.W.; Hamilton, S.H.; Bystritsky, A.; Nemeroff, C.B.; Meyers, B.S. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Fluoxetine collaborative study group. Am. J. Geriatr. Psychiatry 1997, 5, 97-106. [CrossRef] [PubMed]
60. Kono, S.; Sunagawa, Y.; Higa, H.; Sunagawa, H. Age of menopause in japanese women: Trends and recent changes. Maturitas 1990, 12, 43-49. [CrossRef]
61. Mansoor, B.; Rengasamy, M.; Hilton, R.; Porta, G.; He, J.; Spirito, A.; Emslie, G.J.; Mayes, T.L.; Clarke, G.; Wagner, K.D.; et al. The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression. J. Child Adolesc. Psychopharmacol. 2013, 23, 458-467. [CrossRef] [PubMed]
62. Tschritter, O.; Preissl, H.; Hennige, A.M.; Stumvoll, M.; Porubska, K.; Frost, R.; Marx, H.; Klosel, B.; Lutzenberger, W.; Birbaumer, N.; et al. The cerebrocortical response to hyperinsulinemia is reduced in overweight humans: A magnetoencephalographic study. Proc. Natl. Acad. Sci. USA 2006, 103, 12103-12108. [CrossRef] [PubMed]
63. Ryan, J.P.; Sheu, L.K.; Critchley, H.D.; Gianaros, P.J. A neural circuitry linking insulin resistance to depressed mood. Psychosom. Med. 2012, 74, 476-482. [CrossRef] [PubMed]
64. Kullmann, S.; Heni, M.; Veit, R.; Scheffler, K.; Machann, J.; Haring, H.U.; Fritsche, A.; Preissl, H. Selective insulin resistance in homeostatic and cognitive control brain areas in overweight and obese adults. Diabetes Care 2015, 38, 1044-1050. [CrossRef] [PubMed]
65. Anthony, K.; Reed, L.J.; Dunn, J.T.; Bingham, E.; Hopkins, D.; Marsden, P.K.; Amiel, S.A. Attenuation of insulin-evoked responses in brain networks controlling appetite and reward in insulin resistance: The cerebral basis for impaired control of food intake in metabolic syndrome? Diabetes 2006, 55, 2986-2992. [CrossRef] [PubMed]
66. Kullmann, S.; Heni, M.; Veit, R.; Ketterer, C.; Schick, F.; Haring, H.U.; Fritsche, A.; Preissl, H. The obese brain: Association of body mass index and insulin sensitivity with resting state network functional connectivity. Hum. Brain Mapp. 2012, 33, 1052-1061. [CrossRef] [PubMed]
67. Giacobbe, P.; Mayberg, H.S.; Lozano, A.M. Treatment resistant depression as a failure of brain homeostatic mechanisms: Implications for deep brain stimulation. Exp. Neurol. 2009, 219, 44-52. [CrossRef] [PubMed]
68. Gasquoine, P.G. Localization of function in anterior cingulate cortex: From psychosurgery to functional neuroimaging. Neurosci. Biobehav. Rev. 2013, 37, 340-348. [CrossRef] [PubMed]
69. Hauptman, J.S.; DeSalles, A.A.; Espinoza, R.; Sedrak, M.; Ishida, W. Potential surgical targets for deep brain stimulation in treatment-resistant depression. Neurosurg. Focus 2008, 25, E3. [CrossRef] [PubMed]
70. Lener, M.S.; Iosifescu, D.V. In pursuit of neuroimaging biomarkers to guide treatment selection in major depressive disorder: A review of the literature. Ann. N. Y. Acad. Sci. 2015, 1344, 50-65. [CrossRef] [PubMed]
71. Musselman, D.L.; Betan, E.; Larsen, H.; Phillips, L.S. Relationship of depression to diabetes types 1 and 2: Epidemiology, biology, and treatment. Biol. Psychiatry 2003, 54, 317-329. [CrossRef]
72. Drevets, W.C. Neuroimaging studies of mood disorders. Biol. Psychiatry 2000, 48, 813-829. [CrossRef]
73. Osby, U.; Brandt, L.; Correia, N.; Ekbom, A.; Sparen, P. Excess mortality in bipolar and unipolar disorder in sweden. Arch. Gen. Psychiatry 2001, 58, 844-850. [CrossRef] [PubMed]
74. McIntyre, R.S.; Soczynska, J.K.; Konarski, J.Z.; Woldeyohannes, H.O.; Law, C.W.; Miranda, A.; Fulgosi, D.; Kennedy, S.H. Should depressive syndromes be reclassified as "metabolic syndrome type II"? Ann. Clin. Psychiatry 2007, 19, 257-264. [CrossRef] [PubMed]
75. Craft, S.;Watson, G.S. Insulin and neurodegenerative disease: Shared and specific mechanisms. Lancet Neurol. 2004, 3, 169-178. [CrossRef]
76. McEwen, B.S.; Magarinos, A.M.; Reagan, L.P. Studies of hormone action in the hippocampal formation: Possible relevance to depression and diabetes. J. Psychosom. Res. 2002, 53, 883-890. [CrossRef]
77. Masters, B.A.; Shemer, J.; Judkins, J.H.; Clarke, D.W.; le Roith, D.; Raizada, M.K. Insulin receptors and insulin action in dissociated brain cells. Brain Res. 1987, 417, 247-256. [CrossRef]
78. Shibata, S.; Liou, S.Y.; Ueki, S.; Oomura, Y. Inhibitory action of insulin on suprachiasmatic nucleus neurons in rat hypothalamic slice preparations. Physiol. Behav. 1986, 36, 79-81. [CrossRef]
79. Broderick, P.A.; Jacoby, J.H. Central monoamine dysfunction in diabetes: Psychotherapeutic implications: Electroanalysis by voltammetry. Acta Physiol. Pharmacol. Latinoam. 1989, 39, 211-225. [PubMed]
80. Chen, C.C.; Yang, J.C. Effects of short and long-lasting diabetes mellitus on mouse brain monoamines. Brain Res. 1991, 552, 175-179. [CrossRef]
81. Lackovic, Z.; Salkovic, M.; Kuci, Z.; Relja, M. Effect of long-lasting diabetes mellitus on rat and human brain monoamines. J. Neurochem. 1990, 54, 143-147. [CrossRef] [PubMed]
82. Sandrini, M.; Vitale, G.; Vergoni, A.V.; Ottani, A.; Bertolini, A. Streptozotocin-induced diabetes provokes changes in serotonin concentration and on 5-HT1A and 5-HT2 receptors in the rat brain. Life Sci. 1997, 60, 1393-1397. [CrossRef]
83. Li, J.X.; France, C.P. Food restriction and streptozotocin treatment decrease 5-HT1A and 5-HT2A receptor-mediated behavioral effects in rats. Behav. Pharmacol. 2008, 19, 292-297. [CrossRef] [PubMed]
84. Yanagita, T.; Nemoto, T.; Satoh, S.; Yoshikawa, N.; Maruta, T.; Shiraishi, S.; Sugita, C.; Murakami, M. Neuronal insulin receptor signaling: A potential target for the treatment of cognitive and mood disorders. INTECH Open Access Ment. Behav. Disord. Dis. Nervous Syst. 2013, 263-287.
85. Duman, R.S.; Voleti, B. Signaling pathways underlying the pathophysiology and treatment of depression: Novel mechanisms for rapid-acting agents. Trends Neurosci. 2012, 35, 47-56. [CrossRef] [PubMed]
86. Dandona, P.; Aljada, A.; Chaudhuri, A.; Mohanty, P.; Garg, R. Metabolic syndrome: A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005, 111, 1448-1454. [CrossRef] [PubMed]
87. Kloting, N.; Bluher, M. Adipocyte dysfunction, inflammation and metabolic syndrome. Rev. Endocr. Metab. Disord. 2014, 15, 277-287. [CrossRef] [PubMed]
88. Xu, H.; Barnes, G.T.; Yang, Q.; Tan, G.; Yang, D.; Chou, C.J.; Sole, J.; Nichols, A.; Ross, J.S.; Tartaglia, L.A.; et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Investig. 2003, 112, 1821-1830. [CrossRef] [PubMed]
89. Quan, N.; Banks, W.A. Brain-immune communication pathways. Brain Behav. Immun. 2007, 21, 727-735. [CrossRef] [PubMed]
90. Goehler, L.E.; Erisir, A.; Gaykema, R.P. Neural-immune interface in the rat area postrema. Neuroscience 2006, 140, 1415-1434. [CrossRef] [PubMed]
91. Shelton, R.C.; Miller, A.H. Inflammation in depression: Is adiposity a cause? Dialogues Clin. Neurosci. 2011, 13, 41-53. [PubMed]
92. Shelton, R.C.; Miller, A.H. Eating ourselves to death (and despair): The contribution of adiposity and inflammation to depression. Prog. Neurobiol. 2010, 91, 275-299. [CrossRef] [PubMed]
93. Yamada, N.; Katsuura, G.; Ochi, Y.; Ebihara, K.; Kusakabe, T.; Hosoda, K.; Nakao, K. Impaired cns leptin action is implicated in depression associated with obesity. Endocrinology 2011, 152, 2634-2643. [CrossRef] [PubMed]
94. Haroon, E.; Raison, C.L.; Miller, A.H. Psychoneuroimmunology meets neuropsychopharmacology: Translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012, 37, 137-162. [CrossRef] [PubMed]
95. Kemp, D.E.; Ismail-Beigi, F.; Ganocy, S.J.; Conroy, C.; Gao, K.; Obral, S.; Fein, E.; Findling, R.L.; Calabrese, J.R. Use of insulin sensitizers for the treatment of major depressive disorder: A pilot study of pioglitazone for major depression accompanied by abdominal obesity. J. Affect. Disord. 2012, 136, 1164-1173. [CrossRef] [PubMed]
96. Leboyer, M.; Soreca, I.; Scott, J.; Frye, M.; Henry, C.; Tamouza, R.; Kupfer, D.J. Can bipolar disorder be viewed as a multi-system inflammatory disease? J. Affect. Disord. 2012, 141, 1-10. [CrossRef] [PubMed]
97. Jun, T.Y.; Pae, C.U.; Hoon, H.; Chae, J.H.; Bahk, W.M.; Kim, K.S.; Serretti, A. Possible association between -G308A tumour necrosis factor-α gene polymorphism and major depressive disorder in the korean population. Psychiatr. Genet. 2003, 13, 179-181. [CrossRef] [PubMed]
98. Yu, Y.W.; Chen, T.J.; Hong, C.J.; Chen, H.M.; Tsai, S.J. Association study of the interleukin-1 β (C-511T) genetic polymorphism with major depressive disorder, associated symptomatology, and antidepressant response. Neuropsychopharmacology 2003, 28, 1182-1185. [CrossRef] [PubMed]
99. Benedetti, F.; Lucca, A.; Brambilla, F.; Colombo, C.; Smeraldi, E. Interleukine-6 serum levels correlate with response to antidepressant sleep deprivation and sleep phase advance. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26, 1167-1170. [CrossRef]
100. Yoshimura, R.; Hori, H.; Ikenouchi-Sugita, A.; Umene-Nakano,W.; Ueda, N.; Nakamura, J. Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33, 722-726. [CrossRef] [PubMed]
101. Miller, G.E.; Stetler, C.A.; Carney, R.M.; Freedland, K.E.; Banks,W.A. Clinical depression and inflammatory risk markers for coronary heart disease. Am. J. Cardiol. 2002, 90, 1279-1283. [CrossRef]
102. Thomas, A.J.; Davis, S.; Morris, C.; Jackson, E.; Harrison, R.; O'Brien, J.T. Increase in interleukin-1β in late-life depression. Am. J. Psychiatry 2005, 162, 175-177. [CrossRef] [PubMed]
103. Aguirre, V.; Uchida, T.; Yenush, L.; Davis, R.; White, M.F. The c-jun NH2-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser307. J. Biol. Chem. 2000, 275, 9047-9054. [CrossRef] [PubMed]
104. Pomytkin, I.A.; Cline, B.H.; Anthony, D.C.; Steinbusch, H.W.; Lesch, K.P.; Strekalova, T. Endotoxaemia resulting from decreased serotonin tranporter (5-HTT) function: A reciprocal risk factor for depression and insulin resistance? Behav. Brain Res. 2015, 276, 111-117. [CrossRef] [PubMed]
105. Weichhart, T.; Saemann, M.D. The PI3K/Akt/mTOR pathway in innate immune cells: Emerging therapeutic applications. Ann. Rheum. Dis. 2008, 67 (Suppl. S3), iii70-iii74. [CrossRef] [PubMed]
106. Kitagishi, Y.; Kobayashi, M.; Kikuta, K.; Matsuda, S. Roles of PI3K/Akt/GSK3/mTOR pathway in cell signaling of mental illnesses. Depression Res. Treat. 2012, 2012. [CrossRef] [PubMed]
107. Kim, J.Y.; Duan, X.; Liu, C.Y.; Jang, M.H.; Guo, J.U.; Pow-anpongkul, N.; Kang, E.; Song, H.; Ming, G.L. DISC1 regulates new neuron development in the adult brain via modulation of Akt-mTOR signaling through KIAA1212. Neuron 2009, 63, 761-773. [CrossRef] [PubMed]
108. Beaulieu, J.M.; Gainetdinov, R.R.; Caron, M.G. Akt/GSK3 signaling in the action of psychotropic drugs. Annu. Rev. Pharmacol. Toxicol. 2009, 49, 327-347. [CrossRef] [PubMed]
109. Sheppard, K.; Kinross, K.M.; Solomon, B.; Pearson, R.B.; Phillips, W.A. Targeting PI3 kinase/Akt/mTOR signaling in cancer. Crit. Rev. Oncog. 2012, 17, 69-95. [CrossRef] [PubMed]
110. Okumura, N.; Yoshida, H.; Kitagishi, Y.; Murakami, M.; Nishimura, Y.; Matsuda, S. PI3K/Akt/PTEN signaling as a molecular target in leukemia angiogenesis. Adv. Hematol. 2012, 2012. [CrossRef] [PubMed]
111. Fried, S.K.; Bunkin, D.A.; Greenberg, A.S. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: Depot difference and regulation by glucocorticoid. J. Clin. Endocrinol. Metab. 1998, 83, 847-850. [CrossRef] [PubMed]
112. Fleet-Michaliszyn, S.B.; Soreca, I.; Otto, A.D.; Jakicic, J.M.; Fagiolini, A.; Kupfer, D.J.; Goodpaster, B.H. A prospective observational study of obesity, body composition, and insulin resistance in 18 women with bipolar disorder and 17 matched control subjects. J. Clin. Psychiatry 2008, 69, 1892-1900. [CrossRef] [PubMed]
113. Lee, Y.H.; Giraud, J.; Davis, R.J.; White, M.F. C-jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade. J. Biol. Chem. 2003, 278, 2896-2902. [CrossRef] [PubMed]
114. Gould, T.D.; Manji, H.K. Glycogen synthase kinase-3: A putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 2005, 30, 1223-1237. [CrossRef] [PubMed]
115. Papazoglou, I.K.; Jean, A.; Gertler, A.; Taouis, M.; Vacher, C.M. Hippocampal GSK3β as a molecular link between obesity and depression. Mol. Neurobiol. 2015, 52, 363-374. [CrossRef] [PubMed]
116. Girgis, R.R.; Javitch, J.A.; Lieberman, J.A. Antipsychotic drug mechanisms: Links between therapeutic effects, metabolic side effects and the insulin signaling pathway. Mol. Psychiatry 2008, 13, 918-929. [CrossRef] [PubMed]
117. Mao, Z.; Liu, L.; Zhang, R.; Li, X. Lithium reduces FOXO3a transcriptional activity by decreasing its intracellular content. Biol. Psychiatry 2007, 62, 1423-1430. [CrossRef] [PubMed]
118. Polter, A.; Yang, S.; Zmijewska, A.A.; van Groen, T.; Paik, J.-H.; DePinho, R.A.; Peng, S.L.; Jope, R.S.; Li, X. Forkhead box, class o transcription factors in brain: Regulation and behavioral manifestation. Biol. Psychiatry 2009, 65, 150-159. [CrossRef] [PubMed]
119. Huang, W.; Zhao, Y.; Zhu, X.; Cai, Z.; Wang, S.; Yao, S.; Qi, Z.; Xie, P. Fluoxetine upregulates phosphorylated-Akt and phosphorylated-ERK1/2 proteins in neural stem cells: Evidence for a crosstalk between Akt and ERK1/2 pathways. J. Mol. Neurosci. 2013, 49, 244-249. [CrossRef] [PubMed]
120. Li, X.; Jope, R.S. Is glycogen synthase kinase-3 a centralmodulator inmood regulation?Neuropsychopharmacology 2010, 35, 2143-2154. [CrossRef] [PubMed]
121. Cowen, D.S.; Johnson-Farley, N.N.; Travkina, T. 5-HT1A receptors couple to activation of Akt, but not extracellular-regulated kinase (ERK), in cultured hippocampal neurons. J. Neurochem. 2005, 93, 910-917. [CrossRef] [PubMed]
122. Leone, A.M.; Errico, M.; Lin, S.L.; Cowen, D.S. Activation of extracellular signal-regulated kinase (ERK) and Akt by human serotonin 5-HT1B receptors in transfected BE(2)-C neuroblastoma cells is inhibited by RGS4. J. Neurochem. 2000, 75, 934-938. [CrossRef] [PubMed]
123. Gómez, D.P.T.; Velasco, G.; Guzman, M. The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem. J. 2000, 347, 369-373. [CrossRef]
124. Mai, L.; Jope, R.S.; Li, X. BDNF-mediated signal transduction is modulated by GSK3β and mood stabilizing agents. J. Neurochem. 2002, 82, 75-83. [CrossRef] [PubMed]
125. Zheng, W.-H.; Kar, S.; Quirion, R. FKHRL1 and its homologs are new targets of nerve growth factor Trk receptor signaling. J. Neurochem. 2002, 80, 1049-1061. [CrossRef] [PubMed]
126. Johnson-Farley, N.N.; Travkina, T.; Cowen, D.S. Cumulative activation of Akt and consequent inhibition of glycogen synthase kinase-3 by brain-derived neurotrophic factor and insulin-like growth factor-1 in cultured hippocampal neurons. J. Pharmacol. Exp. Ther. 2006, 316, 1062-1069. [CrossRef] [PubMed]
127. Hui, L.; Pei, D.-S.; Zhang, Q.-G.; Guan, Q.-H.; Zhang, G.-Y. The neuroprotection of insulin on ischemic brain injury in rat hippocampus through negative regulation of JNK signaling pathway by PI3K/Akt activation. Brain Res. 2005, 1052, 1-9. [CrossRef] [PubMed]
128. Lee, C.-C.; Huang, C.-C.; Wu, M.-Y.; Hsu, K.-S. Insulin stimulates postsynaptic density-95 protein translation via the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway. J. Biol. Chem. 2005, 280, 18543-18550. [CrossRef] [PubMed]
129. Aulston, B.D.; Odero, G.L.; Glazner, G.W.; Aboud, Z. Alzheimer's Disease and Diabetes; INTECH Open Access Publisher: Hampshire, UK, 2013.
130. Leonard, B.E. The concept of depression as a dysfunction of the immune system. Curr. Immunol. Rev. 2010, 6, 205-212. [CrossRef] [PubMed]
131. Daniele, S.; da Pozzo, E.; Zappelli, E.; Martini, C. Trazodone treatment protects neuronal-like cells from inflammatory insult by inhibiting NF-κB, p38 and JNK. Cell Signal. 2015, 27, 1609-1629. [CrossRef] [PubMed]
132. Encinas, M.; Iglesias, M.; Llecha, N.; Comella, J.X. Extracellular-regulated kinases and phosphatidylinositol 3-kinase are involved in brain-derived neurotrophic factor-mediated survival and neuritogenesis of the neuroblastoma cell line SH-SY5Y. J. Neurochem. 1999, 73, 1409-1421. [CrossRef] [PubMed]
133. Pugazhenthi, S.; Nesterova, A.; Sable, C.; Heidenreich, K.A.; Boxer, L.M.; Heasley, L.E.; Reusch, J.E. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J. Biol. Chem. 2000, 275, 10761-10766. [CrossRef] [PubMed]
134. Xing, J.; Kornhauser, J.M.; Xia, Z.; Thiele, E.A.; Greenberg, M.E. Nerve growth factor activates extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways to stimulate CREB serine 133 phosphorylation. Mol. Cell. Biol. 1998, 18, 1946-1955. [CrossRef] [PubMed]
135. Finkbeiner, S. CREB couples neurotrophin signals to survival messages. Neuron 2000, 25, 11-14. [CrossRef]
136. Hardingham, G.E.; Fukunaga, Y.; Bading, H. Extrasynaptic nmdars oppose synaptic nmdars by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 2002, 5, 405-414. [CrossRef] [PubMed]
137. Ongur, D.; Drevets,W.C.; Price, J.L. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc. Natl. Acad. Sci. USA 1998, 95, 13290-13295. [CrossRef] [PubMed]
138. Anisman, H.; Merali, Z.; Hayley, S. Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: Comorbidity between depression and neurodegenerative disorders. Prog. Neurobiol. 2008, 85, 1-74. [CrossRef] [PubMed]
139. Perera, T.D.; Coplan, J.D.; Lisanby, S.H.; Lipira, C.M.; Arif, M.; Carpio, C.; Spitzer, G.; Santarelli, L.; Scharf, B.; Hen, R.; et al. Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman primates. J. Neurosci. 2007, 27, 4894-4901. [CrossRef] [PubMed]
140. Santarelli, L.; Saxe, M.; Gross, C.; Surget, A.; Battaglia, F.; Dulawa, S.; Weisstaub, N.; Lee, J.; Duman, R.; Arancio, O.; et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301, 805-809. [CrossRef] [PubMed]
141. Myint, A.M.; Kim, Y.K.; Verkerk, R.; Scharpe, S.; Steinbusch, H.; Leonard, B. Kynurenine pathway in major depression: Evidence of impaired neuroprotection. J. Affect. Disord. 2007, 98, 143-151. [CrossRef] [PubMed]
142. Muller, N.; Schwarz, M.J. The immune-mediated alteration of serotonin and glutamate: Towards an integrated view of depression. Mol. Psychiatry 2007, 12, 988-1000. [CrossRef] [PubMed]
143. Moron, J.A.; Zakharova, I.; Ferrer, J.V.; Merrill, G.A.; Hope, B.; Lafer, E.M.; Lin, Z.C.; Wang, J.B.; Javitch, J.A.; Galli, A.; et al. Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J. Neurosci. 2003, 23, 8480-8488. [PubMed]
144. Zhu, C.B.; Blakely, R.D.; Hewlett,W.A. The proinflammatory cytokines interleukin-1β and tumor necrosis factor-α activate serotonin transporters. Neuropsychopharmacology 2006, 31, 2121-2131. [PubMed]
145. Schwarcz, R.; Whetsell, W.O., Jr.; Mangano, R.M. Quinolinic acid: An endogenous metabolite that produces axon-sparing lesions in rat brain. Science 1983, 219, 316-318. [CrossRef] [PubMed]
146. D'Aquila, P.S.; Collu, M.; Gessa, G.L.; Serra, G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur. J. Pharmacol. 2000, 405, 365-373. [CrossRef]
147. Myint, A.M.; Kim, Y.K. Cytokine-serotonin interaction through ido: A neurodegeneration hypothesis of depression. Med. Hypotheses 2003, 61, 519-525. [CrossRef]
148. Chrysohoou, C.; Panagiotakos, D.B.; Pitsavos, C.; Skoumas, I.; Papademetriou, L.; Economou, M.; Stefanadis, C. The implication of obesity on total antioxidant capacity in apparently healthy men and women: The attica study. Nutr. Metab. Cardiovasc. Dis. 2007, 17, 590-597. [CrossRef] [PubMed]
149. Chai, W.; Conroy, S.M.; Maskarinec, G.; Franke, A.A.; Pagano, I.S.; Cooney, R.V. Associations between obesity and serum lipid-soluble micronutrients among premenopausal women. Nutr. Res. 2010, 30, 227-232. [CrossRef] [PubMed]
150. Galan, P.; Viteri, F.E.; Bertrais, S.; Czernichow, S.; Faure, H.; Arnaud, J.; Ruffieux, D.; Chenal, S.; Arnault, N.; Favier, A.; et al. Serum concentrations of β-carotene, vitamins C and E, zinc and selenium are influenced by sex, age, diet, smoking status, alcohol consumption and corpulence in a general french adult population. Eur. J. Clin. Nutr. 2005, 59, 1181-1190. [CrossRef] [PubMed]
151. Maes, M.; Kubera, M.; Obuchowiczwa, E.; Goehler, L.; Brzeszcz, J. Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinol. Lett. 2011, 32, 7-24. [PubMed]
152. Maes, M.; Galecki, P.; Chang, Y.S.; Berk, M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog. Neuro Psychopharmacol. Biol. Psychiatry 2011, 35, 676-692.
153. Maes, M.; Vandoolaeghe, E.; Neels, H.; Demedts, P.;Wauters, A.; Meltzer, H.Y.; Altamura, C.; Desnyder, R. Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness. Biol. Psychiatry 1997, 42, 349-358. [CrossRef]
154. Maes, M.; Mihaylova, I.; Kubera, M.; Uytterhoeven, M.; Vrydags, N.; Bosmans, E. Lower plasma coenzyme Q10 in depression: A marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness. Neuro Endocrinol. Lett. 2009, 30, 462-469. [PubMed]
155. Maes, M.; Mihaylova, I.; Kubera, M.; Leunis, J.C.; Geffard, M. IgM-mediated autoimmune responses directed against multiple neoepitopes in depression: New pathways that underpin the inflammatory and neuroprogressive pathophysiology. J. Affect. Disord. 2011, 135, 414-418. [CrossRef] [PubMed]
156. Moylan, S.; Maes, M.; Wray, N.R.; Berk, M. The neuroprogressive nature of major depressive disorder: Pathways to disease evolution and resistance, and therapeutic implications. Mol. Psychiatry 2013, 18, 595-606. [CrossRef] [PubMed]
157. Arlt, S.; Kontush, A.; Muller-Thomsen, T.; Beisiegel, U. Lipid peroxidation as a common pathomechanism in coronary heart disease and Alzheimer disease. Z. Gerontol. Geriatr. 2001, 34, 461-465. [CrossRef] [PubMed]
158. Sultana, R.; Perluigi, M.; Butterfield, D.A. Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: Insights into mechanism of neurodegeneration from redox proteomics. Antioxid. Redox Signal. 2006, 8, 2021-2037. [CrossRef] [PubMed]
159. Greilberger, J.; Koidl, C.; Greilberger, M.; Lamprecht, M.; Schroecksnadel, K.; Leblhuber, F.; Fuchs, D.; Oettl, K. Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer's disease. Free Radic. Res. 2008, 42, 633-638. [CrossRef] [PubMed]
160. Maes, M.; Ruckoanich, P.; Chang, Y.S.; Mahanonda, N.; Berk, M. Multiple aberrations in shared inflammatory and oxidative & nitrosative stress (IO&NS) pathways explain the co-association of depression and cardiovascular disorder (CVD), and the increased risk for CVD and due mortality in depressed patients. Prog. Neuro Psychopharmacol. Biol. Psychiatry 2011, 35, 769-783.
161. Matute, C.; Domercq, M.; Sanchez-Gomez, M.V. Glutamate-mediated glial injury: Mechanisms and clinical importance. Glia 2006, 53, 212-224. [CrossRef] [PubMed]
162. Ida, T.; Hara, M.; Nakamura, Y.; Kozaki, S.; Tsunoda, S.; Ihara, H. Cytokine-induced enhancement of calcium-dependent glutamate release from astrocytes mediated by nitric oxide. Neurosci. Lett. 2008, 432, 232-236. [CrossRef] [PubMed]
163. Bengesser, S.A.; Lackner, N.; Birner, A.; Fellendorf, F.T.; Platzer, M.; Mitteregger, A.; Unterweger, R.; Reininghaus, B.; Mangge, H.; Wallner-Liebmann, S.J.; et al. Peripheral markers of oxidative stress and antioxidative defense in euthymia of bipolar disorder-Gender and obesity effects. J. Affect. Disord. 2015, 172, 367-374. [CrossRef] [PubMed]
164. Sarandol, A.; Sarandol, E.; Eker, S.S.; Erdinc, S.; Vatansever, E.; Kirli, S. Major depressive disorder is accompanied with oxidative stress: Short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum. Psychopharmacol. 2007, 22, 67-73. [CrossRef] [PubMed]
165. Andreazza, A.C.; Frey, B.N.; Erdtmann, B.; Salvador, M.; Rombaldi, F.; Santin, A.; Goncalves, C.A.; Kapczinski, F. DNA damage in bipolar disorder. Psychiatry Res. 2007, 153, 27-32. [CrossRef] [PubMed]
166. Vargas, H.O.; Nunes, S.O.; Pizzo de Castro, M.; Bortolasci, C.C.; Sabbatini Barbosa, D.; Kaminami Morimoto, H.; Venugopal, K.; Dodd, S.; Maes, M.; Berk, M. Oxidative stress and lowered total antioxidant status are associated with a history of suicide attempts. J. Affect. Disord. 2013, 150, 923-930. [CrossRef] [PubMed]
167. McCloughen, A.; Foster, K. Weight gain associated with taking psychotropic medication: An integrative review. Int. J. Ment. Health Nurs. 2011, 20, 202-222. [CrossRef] [PubMed]
168. Levitan, R.D.; Davis, C.; Kaplan, A.S.; Arenovich, T.; Phillips, D.I.; Ravindran, A.V. Obesity comorbidity in unipolar major depressive disorder: Refining the core phenotype. J. Clin. Psychiatry 2012, 73, 1119-1124. [CrossRef] [PubMed]
169. Vogelzangs, N.; Beekman, A.T.; Boelhouwer, I.G.; Bandinelli, S.; Milaneschi, Y.; Ferrucci, L.; Penninx, B.W. Metabolic depression: A chronic depressive subtype? Findings from the inchianti study of older persons. J. Clin. Psychiatry 2011, 72, 598-604. [CrossRef] [PubMed]
170. Yim, C.Y.; Soczynska, J.K.; Kennedy, S.H.;Woldeyohannes, H.O.; Brietzke, E.; McIntyre, R.S. The effect of overweight/obesity on cognitive function in euthymic individuals with bipolar disorder. Eur. Psychiatry 2012, 27, 223-228. [CrossRef] [PubMed]
171. Rosenblat, J.D.; Brietzke, E.; Mansur, R.B.; Maruschak, N.A.; Lee, Y.; McIntyre, R.S. Inflammation as a neurobiological substrate of cognitive impairment in bipolar disorder: Evidence, pathophysiology and treatment implications. J. Affect. Disord. 2015, 188, 149-159. [CrossRef] [PubMed]